Nations Financial Group Inc. IA ADV Raises Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Nations Financial Group Inc. IA ADV increased its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 6.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 23,492 shares of the medical instruments supplier’s stock after purchasing an additional 1,412 shares during the period. Nations Financial Group Inc. IA ADV’s holdings in LeMaitre Vascular were worth $2,165,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. NBC Securities Inc. increased its position in shares of LeMaitre Vascular by 73.2% in the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 183 shares during the last quarter. KBC Group NV increased its position in shares of LeMaitre Vascular by 58.4% in the fourth quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier’s stock worth $102,000 after purchasing an additional 410 shares during the last quarter. Empowered Funds LLC bought a new position in shares of LeMaitre Vascular in the fourth quarter worth approximately $150,000. SG Americas Securities LLC bought a new position in shares of LeMaitre Vascular in the fourth quarter worth approximately $158,000. Finally, Advisors Asset Management Inc. increased its position in shares of LeMaitre Vascular by 180.2% in the third quarter. Advisors Asset Management Inc. now owns 1,852 shares of the medical instruments supplier’s stock worth $172,000 after purchasing an additional 1,191 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have commented on LMAT. Barrington Research increased their price target on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research report on Friday, November 1st. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Wells Fargo & Company began coverage on shares of LeMaitre Vascular in a research report on Thursday. They set an “equal weight” rating and a $95.00 price target on the stock. Finally, Oppenheimer reiterated an “outperform” rating and set a $93.00 price target (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $94.63.

LeMaitre Vascular Stock Performance

NASDAQ:LMAT opened at $98.65 on Friday. The firm has a market cap of $2.22 billion, a PE ratio of 53.91, a price-to-earnings-growth ratio of 2.19 and a beta of 0.96. LeMaitre Vascular, Inc. has a fifty-two week low of $59.87 and a fifty-two week high of $109.58. The business has a 50 day moving average price of $95.94 and a 200-day moving average price of $93.61.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.